NIOX GroupCSSPF 77 Quick Ratio is 3.20 as of Dec. 2025, which is 31% above its 10-year median of 2.44. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 854 Medical Devices & Instruments companies, NIOX Group ranks better than 69.91% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. NIOX Group's quick ratio for the quarter that ended in Dec. 2025 was 3.20.
NIOX Group has a quick ratio of 3.20. It generally indicates good short-term financial strength.
The historical rank and industry rank for NIOX Group's Quick Ratio or its related term are showing as below:
CSSPF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.4 Med: 2.44 Max: 6.22
Current: 3.2
During the past 13 years, NIOX Group's highest Quick Ratio was 6.22. The lowest was 0.40. And the median was 2.44.
CSSPF's Quick Ratio is ranked better than 69.91% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs CSSPF: 3.20
NIOX Group (OTCPK:CSSPF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
NIOX Group Quick Ratio Related Terms
NIOX Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for NIOX Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where NIOX Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
NIOX Group's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a Quick Ratio of 3.20 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on NIOX Group and its competitors. This is 31% above median its historical median of 2.44. Over the past decade, NIOX Group's Quick Ratio has ranged from 0.40 to 6.22. According to the industry distribution chart, NIOX Group ranks #257 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 30.1%.
Is NIOX Group's Quick Ratio too high?
NIOX Group's current Quick Ratio of 3.20 is 31% above median its 10-year median of 2.44. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 6.22. The Medical Devices & Instruments industry median Quick Ratio is 1.87. NIOX Group's value of 3.20 is 71.6% above this industry median. Based on the distribution chart, NIOX Group ranks #257 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #257 out of 854 companies for Quick Ratio. This puts NIOX Group in the upper half of its industry. The industry median Quick Ratio is 1.87. NIOX Group's value of 3.20 is 71.6% above this benchmark. Historically, NIOX Group's own Quick Ratio has ranged from 0.40 to 6.22 over the past decade. While the company's 10-year median is 2.44 vs. the industry median of 1.87, NIOX Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current Quick Ratio of 3.20 is 71.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current Quick Ratio is 3.20, which is 31% above median its own 10-year median of 2.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.80 — trading 33.9% below its estimated fair value. The current Quick Ratio is 3.20, which is 31% above median its 10-year median of 2.44 and 71.6% above the Medical Devices & Instruments industry median of 1.87. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For NIOX Group (CSSPF), the current Quick Ratio is 3.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.80 is trading 33.9% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
Quick Ratio: 3.20 (31% above median its 10-year median of 2.44)
GF Value™: $1.21 vs. price of $0.80 (33.9% below fair value)
Industry Position: 71.6% above the Medical Devices & Instruments median (#257 of 854)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
